SeraGene Therapeutics

Cover Block

PUBLIC

Name	SeraGene Therapeutics
Tagline	RNA-based nanomedicine therapies for blood coagulation disorders
Headquarters	Vancouver, Canada
Founded	2022
Stage	Seed
Business Model	Other
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	Seed

Links

PUBLIC

• Website: https://www.seragenetx.com/
• LinkedIn: https://ca.linkedin.com/company/seragene-tx

Executive Summary

PUBLIC

SeraGene Therapeutics is a preclinical biotech developing RNA-based nanomedicines to treat blood coagulation disorders, a venture that merits attention for its focus on a high-need, specialized niche and its backing by a strategic, disease-focused venture philanthropy fund [NBDF, Feb 2026]. The company originated as a spinout from the Nanomedicines Innovation Network (NMIN) and the Versiti Blood Research Institute, channeling academic research on clotting biology and lipid nanoparticle (LNP) delivery into a commercial pipeline [Perplexity Sonar Pro Brief]. Its core platform uses proprietary, liver-targeted siRNA delivered via LNPs to precisely modulate the expression of clotting proteins, aiming to create long-acting prophylactic therapies for conditions like hemophilia and thrombosis [NBDF, Feb 2026].

The founding team, which includes Dr. Erika Siren as CEO, is rooted in the academic institutions from which the company spun out, though detailed public bios for all founders are not available [NMIN, Oct 2024]. The company is in its seed stage, having secured a strategic investment from Pathway to Cures, the venture arm of the National Bleeding Disorders Foundation, in November 2025; the round amount is undisclosed [Crunchbase]. SeraGene has also progressed through notable accelerators including adMare BioInnovations and Creative Destruction Lab, which provides ecosystem validation and non-dilutive support [adMare BioInnovations].

Over the next 12 to 18 months, the key milestones to watch are the progression of its lead asset, SG-001, through late preclinical studies, the potential announcement of a formal pharmaceutical partnership, and any subsequent financing round that would fund the transition into clinical trials.

Data Accuracy: YELLOW -- Core technology and recent funding confirmed by primary sources; team details and pipeline specifics are partially corroborated.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	Other
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	Seed

Company Overview

PUBLIC

SeraGene Therapeutics is a preclinical biotechnology company founded in 2022, operating as a spinout from the Versiti Blood Research Institute in Wisconsin and the University of British Columbia's Center for Blood Research [NBDF, Feb 2026]. The company is headquartered in Vancouver, Canada, and was formed with the backing of the Nanomedicines Innovation Network, a Canadian research consortium [NMIN, Oct 2024].

Its early development has been marked by participation in several Canadian life sciences accelerators, including adMare BioInnovations and Creative Destruction Lab, which provided initial validation and support for its RNA-based platform [adMare BioInnovations]. The company secured its first disclosed equity investment in November 2025, a strategic seed round led by the venture philanthropy fund Pathway to Cures [Crunchbase].

Key milestones are primarily recognition-based, signaling ecosystem validation while the technology remains in preclinical stages. SeraGene was named a Company to Watch at the 2024 Life Sciences BC Awards, won a prize at Sweet Pharma Day 2024, and was a finalist in the 2025 Lilly Grand Challenge [NBDF, Feb 2026].

Data Accuracy: YELLOW -- Company origin and accelerator affiliations are confirmed by multiple sources; funding round is confirmed by Crunchbase. Specific founding date and entity details are not independently verified.

Product and Technology

MIXED SeraGene Therapeutics is building a platform for long-acting RNA therapies, a technical approach that aims to shift the treatment paradigm for coagulation disorders from reactive to prophylactic. The company’s core technology involves delivering proprietary small interfering RNA (siRNA) agents to liver cells using targeted lipid nanoparticles (LNPs), a method designed to precisely modulate the expression of clotting proteins in the blood [NBDF, Feb 2026]. The public proposition centers on reducing dosing frequency and improving safety profiles compared to current protein-replacement therapies or systemic anticoagulants.

The platform is reported to support a portfolio of eight patented assets, ranging from discovery to late preclinical stages, with preclinical data generated in large-animal disease models [Perplexity Sonar Pro Brief]. Two lead assets are positioned as potential first-in-class or best-in-class therapies. The company’s flagship program, SG-001, is described as a universal siRNA-based hemostatic agent intended for monthly dosing to treat a wide range of rare bleeding disorders; its mechanism targets mRNA to suppress plasminogen, which is intended to stabilize blood clots [Perplexity Sonar Pro Brief]. A second mechanistic approach aims to enhance the expression of specific genes required for coagulation.

SeraGene’s development pipeline is organized around three thematic areas: innovative prophylactic therapies for rare bleeding disorders, enhanced transfusable platelets for platelet dysfunction, and short- and long-term prophylactic therapies for thrombotic disorders [Perplexity Sonar Pro Brief]. The company is pre-revenue and has not publicly disclosed a clinical development timeline or any partnerships for co-development or licensing.

Data Accuracy: YELLOW -- Core technology and pipeline themes are described in a primary source profile [NBDF, Feb 2026]; asset count and mechanistic details are from a single aggregated research brief.

Market Research

PUBLIC

The push for durable, prophylactic treatments in hematology, particularly for rare disorders, is reshaping a market historically reliant on burdensome protein-replacement therapies and systemic anticoagulants.

SeraGene's focus on RNA-based nanomedicines for coagulation disorders sits within a broader therapeutic shift. The global market for hemophilia treatments alone is projected to reach approximately $20 billion by 2030, driven by high-cost factor replacement therapies and the introduction of novel non-factor products [Grand View Research, 2024]. This analogous market underscores the significant economic weight of conditions SeraGene targets, though the company's specific pipeline for rare bleeding and thrombotic disorders addresses a narrower, more specialized segment. The broader RNA therapeutics market, a key enabling technology, is itself forecast to grow from around $6 billion in 2023 to over $25 billion by 2030, propelled by delivery advances and clinical successes in liver-targeted conditions [Precedence Research, 2024].

Demand drivers for SeraGene's proposed approach are well-documented. There is a clear clinical need for less frequent, prophylactic dosing to improve patient quality of life and reduce the treatment burden associated with current standard-of-care injections, which can be required multiple times per week [National Bleeding Disorders Foundation]. Tailwinds include the validation of lipid nanoparticle (LNP) delivery for RNA payloads, established by COVID-19 vaccines, and a growing venture philanthropy focus on rare diseases. The strategic investment from Pathway to Cures, the venture arm of the National Bleeding Disorders Foundation, directly signals this ecosystem validation and a demand for solutions that address unmet needs in inheritable blood disorders [NBDF, Feb 2026].

Key adjacent markets include gene therapy for hemophilia and other novel anticoagulants. While gene therapies offer potential one-time cures, they carry significant cost, manufacturing complexity, and long-term safety questions, leaving room for intermediary RNA-based approaches that offer multi-month durability with a potentially reversible mechanism. The regulatory pathway for liver-targeted RNAi therapies is also becoming more established, with several FDA and EMA approvals setting precedents for clinical development and review timelines, a factor that reduces regulatory uncertainty for new entrants in the space.

Hemophilia Treatment Market (2030) | 20000 | $M
RNA Therapeutics Market (2030) | 25000 | $M

The cited market sizes, while analogous, illustrate the substantial revenue pools adjacent to SeraGene's niche. Success would require capturing a fraction of the hemophilia market or a segment of the growing RNA therapeutics envelope, a plausible scenario given the targeted mechanism and unmet need.

Data Accuracy: YELLOW -- Market sizing figures are from third-party analyst reports for analogous sectors, not specific to SeraGene's pipeline. Demand drivers are corroborated by foundation and industry sources.

Competitive Landscape

MIXED SeraGene Therapeutics is positioning itself in a niche of the biopharma landscape where RNA-based therapies intersect with hematology, a segment characterized by high scientific barriers and a mix of established protein therapies and emerging genetic approaches.

Given the absence of named, direct competitors in the structured research, a detailed comparison table cannot be constructed. The competitive analysis must therefore proceed on the basis of the broader therapeutic and technological categories in which SeraGene operates.

The competitive map for coagulation disorders is stratified by therapeutic modality and stage of development. On one side are the long-established incumbents: recombinant clotting factor concentrates (from companies like Takeda, Bayer, and Sanofi) and non-factor replacement therapies such as emicizumab (Roche/Genentech). These represent the standard of care, with deep commercial entrenchment and extensive clinical safety data, but they carry burdens of frequent intravenous or subcutaneous administration and, in some cases, significant cost and inhibitor risk. Adjacent to these are newer genetic therapies, most notably the recently approved adeno-associated virus (AAV) gene therapies for hemophilia from BioMarin and Pfizer/Spark Therapeutics. These offer a potential functional cure but are associated with high one-time cost, complex manufacturing, and the long-term safety uncertainties inherent with viral vector integration. SeraGene's proposed edge lies in occupying a middle ground: aiming for the durable, prophylactic effect of a genetic therapy but using a transient, repeatable siRNA/LNP platform that may offer a more favorable safety profile and manufacturing scalability than AAVs [NBDF, Feb 2026].

Where SeraGene claims a defensible edge today is in its specific scientific premise and its aligned, non-dilutive capital. The company's focus on modulating the fibrinolytic pathway (e.g., suppressing plasminogen) via liver-targeted LNPs is a distinct mechanistic approach not widely pursued by larger players [NBDF, Feb 2026]. This technical differentiation is supported by eight patented assets, though these remain in preclinical phases. More tangibly, the strategic investment and portfolio placement from Pathway to Cures, the venture arm of the National Bleeding Disorders Foundation, provides a unique form of validation and potential access to patient community insights and clinical trial networks that pure financial VCs cannot offer [LifeSciences BC, Nov 2025]. This edge is durable only if it translates into accelerated and de-risked clinical development; it perishes if the preclinical data fails to hold up in human trials, at which point the foundational scientific edge would evaporate.

The company's most significant exposure is its preclinical status versus the clinical-stage assets of well-funded competitors. It lacks the human proof-of-concept data that de-risks programs for larger pharmaceutical partners or later-stage investors. Furthermore, it is entering a space where several large biotechs and pharmas have established gene therapy divisions with substantial manufacturing and commercial capabilities. A competitor like Intellia Therapeutics, with its in vivo CRISPR/Cas9 platform delivered via LNPs, could theoretically pivot to coagulation targets, bringing a more mature platform and deeper pockets to the same technological niche. SeraGene also does not own any proprietary commercial channel or distribution; its path to market would inevitably require a partnership with an entity that has hematology sales infrastructure.

In the most plausible 18-month scenario, the competitive landscape will be shaped by early clinical readouts and partnership announcements. The winner in this window will be the company that first demonstrates compelling safety and biomarker data for a long-acting, subcutaneously administered prophylactic in a Phase 1/2 trial. For SeraGene, a 'winner' scenario involves using its NBDF alignment to efficiently enroll a proof-of-concept study for SG-001 and subsequently announcing a co-development deal with a mid-sized hematology-focused biotech. A 'loser' scenario would see the company stall in the preclinical-to-clinical transition, unable to secure the additional capital or partnership needed to initiate trials, while a competitor like Alnylam (with deep RNAi expertise) or a gene editing firm announces a competing coagulation program, effectively crowding out the available funding and strategic interest in the niche.

Data Accuracy: YELLOW -- Competitive context is inferred from therapeutic landscape analysis; specific competitor claims and SeraGene's differentiation are sourced from NBDF and ecosystem materials.

Opportunity

PUBLIC

If SeraGene Therapeutics can translate its preclinical RNA/LNP platform into an approved therapy, it would address a multibillion-dollar market for prophylactic treatments in rare coagulation disorders, an area with profound unmet need.

The headline opportunity is the establishment of a category-defining platform for long-acting, liver-targeted RNA interference in hemostasis. The company's aim is not just a single drug, but a validated delivery system for modulating clotting proteins that could be applied across a spectrum of bleeding and thrombotic conditions [NBDF, Feb 2026]. This outcome is reachable, rather than purely aspirational, because the foundational technology originates from established academic centers of excellence in nanomedicine and blood research, with eight patented assets already spanning discovery to late preclinical stages [Perplexity Sonar Pro Brief]. The strategic investment from Pathway to Cures, the venture philanthropy arm of the National Bleeding Disorders Foundation, provides not just capital but also a direct conduit to the patient community and clinical expertise necessary to guide development [LifeSciences BC, Nov 2025].

Growth would likely follow one of several concrete, high-scale paths. The most direct is winning regulatory approval for a first-in-class prophylactic agent for a rare bleeding disorder, using that success to fund expansion into adjacent, larger indications.

Scenario	What happens	Catalyst	Why it's plausible
Niche-to-Broad Leader	SG-001 gains orphan drug designation and approval for a rare bleeding disorder, establishing proof-of-concept and revenue to fund pipeline expansion into common thrombotic conditions.	Successful completion of a Phase 1/2 clinical trial demonstrating safety and durable target knockdown in patients.	The company's flagship program, SG-001, is already described as a "universal siRNA-based hemostatic agent" intended for monthly dosing, a profile designed for prophylactic use [Perplexity Sonar Pro Brief]. The NBDF's direct backing signals a prioritized unmet need.
Platform Licensing to Big Pharma	A major pharmaceutical company licenses SeraGene's LNP delivery platform for liver-targeted siRNA applications in coagulation, providing non-dilutive funding and validation.	Publication of compelling large-animal model data for a second pipeline asset, demonstrating the platform's modularity.	The company's technology is built on lipid nanoparticles, a delivery modality with proven clinical success in other RNA therapeutic areas, making it an attractive partner for firms seeking to expand their nucleic acid portfolios [Perplexity Sonar Pro Brief].

Compounding success for SeraGene would look like a therapeutic and data flywheel. The first approved therapy would generate crucial human data on the pharmacokinetics and pharmacodynamics of liver-targeted siRNA in coagulation. This real-world evidence would de-risk the development of subsequent pipeline candidates targeting different proteins, potentially reducing trial timelines and costs. Furthermore, an established relationship with hematology clinics and the NBDF network would create a distribution advantage for launching follow-on products, effectively locking in a specialist prescriber base that is difficult for new entrants to access quickly.

The size of the win can be framed by looking at comparable companies that have successfully brought novel therapies for rare hematologic diseases to market. For example, companies like BioMarin Pharmaceutical, which markets therapies for hemophilia and other genetic disorders, trade at market capitalizations in the tens of billions of dollars. While SeraGene is at a far earlier stage, a successful "Niche-to-Broad Leader" scenario that captures even a single niche indication could support a valuation in the low hundreds of millions based on precedent transactions for clinical-stage rare disease assets. If the platform potential is fully realized, the opportunity expands to address common conditions like deep vein thrombosis or stroke prevention, representing a total addressable market measured in the tens of billions annually (scenario, not a forecast).

Data Accuracy: YELLOW -- Opportunity analysis is based on cited company claims and ecosystem validations; market size and comparables are inferred from the broader therapeutic category.

Sources

PUBLIC

1. [NBDF, Feb 2026] Spotlight on SeraGene, a Pathway to Cure's Portfolio Company | https://www.bleeding.org/news/spotlight-on-seragene-a-pathway-to-cures-portfolio-company

2. [Perplexity Sonar Pro Brief] Perplexity Sonar Pro Research Brief |

3. [NMIN, Oct 2024] NMIN spin-off SeraGene wins prize at Sweet Pharma Day | https://www.nanomedicines.ca/2024/10/16/seragene-wins/

4. [Crunchbase] Seed Round - SeraGene Therapeutics | https://www.crunchbase.com/funding_round/seragene-therapeutics-seed--c285ab3e

5. [adMare BioInnovations] SeraGene Therapeutics | https://www.admarebio.com/en/accelerator/seragene-therapeutics-1

6. [LifeSciences BC, Nov 2025] Pathway to Cures Invests in SeraGene Therapeutics | https://lifesciencesbc.ca/members/pathway-to-cures-invests-in-seragene-therapeutics/

7. [Grand View Research, 2024] Hemophilia Treatment Market Size Report, 2024-2030 |

8. [Precedence Research, 2024] RNA Therapeutics Market Size Report, 2024-2030 |

9. [National Bleeding Disorders Foundation] National Bleeding Disorders Foundation | https://www.bleeding.org/